Experimental group:orelabrutinib

2 trials

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, HuZhou Central Hosptial

Conditions

Chronic lymphocytic leukemia/small lymphocytic lymphomaindolent non-Hodgkin lymphoma(iNHL)

Phase 2

A Prospective, Multi-center, Open-Label, Single-Arm Study of Orelabrutinib in Patients with previously treated indolent non-Hodgkin lymphoma (iNHL) Intolerant of previous BTK Inhibitors

RecruitingChiCTR2400080207

HuZhou Central Hosptialindolent non-Hodgkin lymphoma(iNHL)

Start: 2023-09-11Updated: 2024-01-28

Phase 4

A Prospective, Multi-center, Open-label, Single-arm Study of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small cell Lymphocytic Lymphoma Intolerant to Prior BTK Inhibitors

Active, not recruitingChiCTR2300071096

Ruijin Hospital, Shanghai Jiaotong University School of MedicineChronic lymphocytic leukemia/small lymphocytic lymphoma

Start: 2023-05-01Updated: 2023-06-04

Related Papers

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Blood2024-11-05